OnKure Therapeutics (OKUR) Projected to Post Quarterly Earnings on Thursday

OnKure Therapeutics (NASDAQ:OKUR) is expected to post its quarterly earnings results before the market opens on Thursday, March 27th. Analysts expect OnKure Therapeutics to post earnings of ($1.08) per share for the quarter.

OnKure Therapeutics (NASDAQ:OKUR) last posted its earnings results on Monday, March 10th. The company reported ($1.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by ($0.51). On average, analysts expect OnKure Therapeutics to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

OnKure Therapeutics Stock Performance

NASDAQ OKUR opened at $5.00 on Thursday. The business has a fifty day moving average price of $5.54. The company has a market cap of $67.18 million, a price-to-earnings ratio of -0.41 and a beta of 0.28. OnKure Therapeutics has a 1 year low of $4.45 and a 1 year high of $20.00.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. Oppenheimer cut their price target on shares of OnKure Therapeutics from $35.00 to $30.00 and set an “outperform” rating on the stock in a report on Tuesday, March 11th. HC Wainwright cut their price target on shares of OnKure Therapeutics from $40.00 to $34.00 and set a “buy” rating on the stock in a report on Tuesday. Leerink Partners began coverage on shares of OnKure Therapeutics in a report on Thursday, December 5th. They set an “outperform” rating and a $33.00 price objective on the stock. Finally, Leerink Partnrs raised shares of OnKure Therapeutics to a “strong-buy” rating in a report on Thursday, December 5th. Three investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, OnKure Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $32.33.

About OnKure Therapeutics

OnKure Therapeutics, Inc engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer.